GlassScriptPhysician profile
Antonio Scappaticci
NPI 1124031075
$385.94
in general payments reported to CMS, 2019-2025
13 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $386.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $80.72 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $73.21 | 2019 | |
| Amgen INC. | $39.46 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $30.79 | 2019 | |
| Janssen Pharmaceuticals, INC | $25.63 | 2019 | |
| Scilex Pharmaceuticals INC. | $24.08 | 2019 | |
| Amarin Pharma, INC. | $23.76 | 2019 | |
| Novo Nordisk INC | $21.07 | 2019 | |
| Glaxosmithkline, LLC. | $16.50 | 2019 | |
| Sanofi-Aventis U.S. LLC | $15.27 | 2019 | |
| Abbvie INC. | $12.96 | 2019 | |
| Lilly USA, LLC | $11.43 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $11.06 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Antonio Scappaticci listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.